These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 17268531)

  • 1. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
    Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
    Leukemia; 2007 Mar; 21(3):524-8. PubMed ID: 17268531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
    Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
    Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
    Romaguera JE; Fayad LE; McLaughlin P; Pro B; Rodriguez A; Wang M; Weaver P; Hartig K; Kwak LW; Feldman T; Smith J; Ford P; Goldberg S; Pecora A; Goy A
    Br J Haematol; 2010 Oct; 151(1):47-53. PubMed ID: 20735402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
    Orciuolo E; Buda G; Pelosini M; Petrini M
    Br J Haematol; 2010 Mar; 148(5):810-2. PubMed ID: 19919649
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
    Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
    MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
    Wang M; Han XH; Zhang L; Yang J; Qian JF; Shi YK; Kwak LW; Romaguera J; Yi Q
    Leukemia; 2008 Jan; 22(1):179-85. PubMed ID: 17898787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.
    Weigert O; Weidmann E; Mueck R; Bentz M; von Schilling C; Rohrberg R; Jentsch-Ullrich K; Hiddemann W; Dreyling M
    Leuk Lymphoma; 2009 May; 50(5):716-22. PubMed ID: 19347767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
    Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA
    Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
    Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
    Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful bortezomib-based treatment in POEMS syndrome.
    Tang X; Shi X; Sun A; Qiu H; Gu B; Zhou H; Xue S; Liu Y; Ruan C; Wu D
    Eur J Haematol; 2009 Dec; 83(6):609-10. PubMed ID: 19674063
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
    Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
    Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
    Beaven AW; Shea TC; Moore DT; Feldman T; Ivanova A; Ferraro M; Ford P; Smith J; Goy A
    Leuk Lymphoma; 2012 Feb; 53(2):254-8. PubMed ID: 21812533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
    Robak T; Huang H; Jin J; Zhu J; Liu T; Samoilova O; Pylypenko H; Verhoef G; Siritanaratkul N; Osmanov E; Alexeeva J; Pereira J; Drach J; Mayer J; Hong X; Okamoto R; Pei L; Rooney B; van de Velde H; Cavalli F;
    N Engl J Med; 2015 Mar; 372(10):944-53. PubMed ID: 25738670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
    Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
    Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.
    Chang JE; Peterson C; Choi S; Eickhoff JC; Kim K; Yang DT; Gilbert LA; Rogers ES; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
    Br J Haematol; 2011 Oct; 155(2):190-7. PubMed ID: 21848883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib in mantle cell lymphoma.
    Suh KS; Goy A
    Future Oncol; 2008 Apr; 4(2):149-68. PubMed ID: 18407730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    O'Connor OA
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.